NASDAQ:ORTXOrchard Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orchard Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.06 -0.08 (-1.56 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$4.80Now: $5.06▼$5.2050-Day Range$4.95MA: $5.85▼$7.8152-Week Range$4.71Now: $5.06▼$17.48Volume396,753 shsAverage Volume385,908 shsMarket Capitalization$492.16 millionP/E RatioN/ADividend YieldN/ABeta0.96 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.60, Orchard Therapeutics has a potential upside of 386.2% from its current price of $5.06.Amount of Analyst CoverageOrchard Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesOrchard Therapeutics has received 133 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrchard Therapeutics has received 163 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrchard Therapeutics has received 55.07% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote “Outperform” if you believe ORTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by Institutions68.90% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORTX Previous Symbol CUSIPN/A CIKN/A Webwww.orchard-tx.com Phone011-44-0-203-3846700Debt Debt-to-Equity Ratio0.09 Current Ratio6.66 Quick Ratio6.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.51 million Price / Sales196.08 Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book1.63Profitability EPS (Most Recent Fiscal Year)($1.75) Net Income$-163,420,000.00 Net MarginsN/A Return on Equity-57.51% Return on Assets-45.05%Miscellaneous Employees180 Outstanding Shares97,264,000Market Cap$492.16 million Next Earnings Date8/6/2020 (Confirmed) OptionableNot Optionable $5.06 -0.08 (-1.56 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ORTX News and Ratings via Email Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter. Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions How has Orchard Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ORTX stock has decreased by 44.3% and is now trading at $5.06. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Orchard Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Orchard Therapeutics. When is Orchard Therapeutics' next earnings date? Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Orchard Therapeutics. How can I listen to Orchard Therapeutics' earnings call? Orchard Therapeutics will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics PLC - (NASDAQ:ORTX) issued its earnings results on Thursday, May, 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.01. View Orchard Therapeutics' earnings history. What price target have analysts set for ORTX? 5 equities research analysts have issued 12 month target prices for Orchard Therapeutics' shares. Their forecasts range from $17.00 to $31.00. On average, they expect Orchard Therapeutics' share price to reach $24.60 in the next year. This suggests a possible upside of 386.2% from the stock's current price. View analysts' price targets for Orchard Therapeutics. Has Orchard Therapeutics been receiving favorable news coverage? Media coverage about ORTX stock has been trending negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Orchard Therapeutics earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Orchard Therapeutics. Are investors shorting Orchard Therapeutics? Orchard Therapeutics saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 1,960,000 shares, a decrease of 8.4% from the June 30th total of 2,140,000 shares. Based on an average daily volume of 440,600 shares, the short-interest ratio is presently 4.4 days. Approximately 2.4% of the shares of the stock are short sold. View Orchard Therapeutics' Current Options Chain. Who are some of Orchard Therapeutics' key competitors? Some companies that are related to Orchard Therapeutics include Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Legend Biotech (PCVX), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Bill.com (RVMD), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), Forma Therapeutics (FMTX), Coherus Biosciences (CHRS), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX) and Nantkwest (NK). View all competitors. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Range Resources (RRC), bluebird bio (BLUE), Callon Petroleum (CPE), Iovance Biotherapeutics (IOVA), Applied Genetic Technologies (AGTC), Coeur Mining (CDE), Eiger Biopharmaceuticals (EIGR), Heron Therapeutics (HRTX), MEI Pharma (MEIP) and Myovant Sciences (MYOV). Who are Orchard Therapeutics' key executives? Orchard Therapeutics' management team includes the following people: Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)Dr. Anne Dupraz-Poiseau, Chief Regulatory OfficerMr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)Ms. Ran Zheng, Chief Technical OfficerProf. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54) When did Orchard Therapeutics IPO? (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Orchard Therapeutics' stock symbol? Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX." Who are Orchard Therapeutics' major shareholders? Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Regents of The University of California (0.88%) and Leap Investments LP (0.01%). View institutional ownership trends for Orchard Therapeutics. Which major investors are buying Orchard Therapeutics stock? ORTX stock was purchased by a variety of institutional investors in the last quarter, including Regents of The University of California, and Leap Investments LP. View insider buying and selling activity for Orchard Therapeutics. How do I buy shares of Orchard Therapeutics? Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Orchard Therapeutics' stock price today? One share of ORTX stock can currently be purchased for approximately $5.06. How big of a company is Orchard Therapeutics? Orchard Therapeutics has a market capitalization of $492.16 million and generates $2.51 million in revenue each year. The company earns $-163,420,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe. What is Orchard Therapeutics' official website? The official website for Orchard Therapeutics is www.orchard-tx.com. How can I contact Orchard Therapeutics? Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700. This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
